CEO Gary Gillheeney was paid $6,811,754 in fiscal year 2025, ↓ down 2.6% from fiscal year 2024, the 35th percentile of its disclosed peer group (SEC filing 0001193125-26-197357 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,811,754 ↓ Gary Gillheeney total, FY2025 | 35th CEO pay percentile vs peers | 17:1 CEO-to-median pay ratio | 85.07% Say-on-pay support, latest vote |
You have just read Organogenesis Holdings's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper ORGO reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ORGO's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gary Gillheeney | $979,105 | $0 | $2,833,330 | $1,380,017 | $1,536,575 | $0 | $82,727 | $6,811,754 |
| President and Chief Executive Officer | ||||||||
| Brian Grow | 485,123 | 0 | 732,390 | 360,241 | 518,366 | 0 | 47,370 | 2,143,490 |
| Chief Commercial Officer | ||||||||
| Patrick Bilbo | 514,478 | 0 | 736,665 | 362,317 | 441,377 | 0 | 62,091 | 2,116,928 |
| Chief Operating Officer | ||||||||
| Lori Freedman | 518,838 | 0 | 648,295 | 319,422 | 513,081 | 0 | 43,243 | 2,042,879 |
| Chief Administrative and Legal Officer | ||||||||
| David Francisco | 514,626 | 0 | 660,731 | 325,459 | 445,466 | 0 | 40,783 | 1,987,065 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gary Gillheeney | $6,811,754 | $6,993,679 | $6,244,671 | ↓ −181,925 |
| Brian Grow | 2,143,490 | 2,094,553 | 1,924,658 | ↑ +48,937 |
| Patrick Bilbo | 2,116,928 | 2,276,634 | 2,156,855 | ↓ −159,706 |
| Lori Freedman | 2,042,879 | 1,995,053 | 1,994,853 | ↑ +47,826 |
| David Francisco | 1,987,065 | 2,025,754 | 1,629,294 | ↓ −38,689 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses ORGO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ORGO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| David Francisco | CFO | $1,987,065 |
| Gary Gillheeney | CEO | $6,811,754 |
| Brian Grow | CCO | $2,143,490 |
| Lori Freedman | Executive | $2,042,879 |
| Patrick Bilbo | COO | $2,116,928 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alan A. Ades | Former director (through FY2025) | — |
| Arthur S. Leibowitz | Independent Director | $313,606 |
| David Erani | Former director (through FY2025) | — |
| Garrett Lustig | Independent Director | $252,500 |
| Gilberto Quintero | Independent Director | $248,702 |
| Glenn H. Nussdorf | Director | — |
| Jon Giacomin | Independent Director | $269,808 |
| Michael J. Driscoll | Independent Director | $242,692 |
| Michele Korfin | Independent Director | $250,192 |
| Prathyusha Duraibabu | Independent Director | $249,808 |
| Robert Ades | Director | — |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gary Gillheeney | RSU | 2025-02-19 | — | — | 708,215 | — | $2,499,999 |
| Brian Grow | PSU | 2025-02-19 | 12,204 | 24,409 | — | 48,818 | 86,164 |
| Patrick Bilbo | RSU | 2025-02-19 | — | — | 184,136 | — | 650,000 |
| Lori Freedman | PSU | 2025-02-19 | 10,803 | 21,606 | — | 43,212 | 76,269 |
| Lori Freedman | RSU | 2025-02-19 | — | — | 162,047 | — | 572,026 |
| Brian Grow | RSU | 2025-02-19 | — | — | 183,067 | — | 646,227 |
| David Francisco | PSU | 2025-02-19 | 11,010 | 22,020 | — | 44,040 | 77,731 |
| Gary Gillheeney | PSU | 2025-02-19 | 47,214 | 94,428 | — | 188,856 | 333,331 |
| David Francisco | RSU | 2025-02-19 | — | — | 165,156 | — | 583,001 |
| Patrick Bilbo | PSU | 2025-02-19 | 12,275 | 24,551 | — | 49,102 | 86,665 |
| Gary Gillheeney | OPTION | 2025-02-19 | — | — | 732,596 | — | 1,380,017 |
| Lori Freedman | OPTION | 2025-02-19 | — | — | 167,625 | — | 319,422 |
| Brian Grow | OPTION | 2025-02-19 | — | — | 189,369 | — | 360,241 |
| David Francisco | OPTION | 2025-02-19 | — | — | 170,841 | — | 325,459 |
| Patrick Bilbo | OPTION | 2025-02-19 | — | — | 190,475 | — | 362,317 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gary Gillheeney | $2,499,999 | $333,331 | $1,380,017 | 7.9% |
| Brian Grow | 646,227 | 86,164 | 360,241 | 7.9% |
| Patrick Bilbo | 650,000 | 86,665 | 362,317 | 7.9% |
| Lori Freedman | 572,026 | 76,269 | 319,422 | 7.9% |
| David Francisco | 583,001 | 77,731 | 325,459 | 7.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Patrick Bilbo | Option | 254,006 | 3.43 | — |
| Brian Grow | PSU | 48,818 | — | 252,877 |
| Lori Freedman | RSU | 426,746 | — | 2,210,544 |
| David Francisco | Option | 23,923 | 8.03 | — |
| Brian Grow | RSU | 469,960 | — | 2,434,393 |
| David Francisco | Option | 170,841 | 3.53 | — |
| Gary Gillheeney | Option | 166,133 | 8.03 | — |
| Gary Gillheeney | RSU | 1,740,321 | — | 9,014,863 |
| Patrick Bilbo | RSU | 501,550 | — | 2,598,029 |
| David Francisco | RSU | 416,760 | — | 2,158,817 |
| Gary Gillheeney | PSU | 188,856 | — | 978,274 |
| Lori Freedman | Option | 24,809 | 8.03 | — |
| Patrick Bilbo | PSU | 49,102 | — | 254,348 |
| David Francisco | PSU | 44,040 | — | 228,127 |
| Lori Freedman | PSU | 43,212 | — | 223,838 |
| Patrick Bilbo | Option | 194,327 | 2.51 | — |
| Gary Gillheeney | Option | 732,596 | 3.53 | — |
| Gary Gillheeney | Option | 827,691 | 2.51 | — |
| Gary Gillheeney | Option | 929,047 | 3.43 | — |
| David Francisco | Option | 143,946 | 2.51 | — |
| David Francisco | Option | 217,437 | 3.43 | — |
| Patrick Bilbo | Option | 190,475 | 3.53 | — |
| Patrick Bilbo | Option | 31,380 | 8.03 | — |
| Lori Freedman | Option | 165,538 | 2.51 | — |
| Lori Freedman | Option | 207,553 | 3.43 | — |
| Lori Freedman | Option | 167,625 | 3.53 | — |
| Brian Grow | Option | 26,766 | 8.03 | — |
| Brian Grow | Option | 172,735 | 2.51 | — |
| Brian Grow | Option | 235,227 | 3.43 | — |
| Brian Grow | Option | 189,369 | 3.53 | — |
The compensation of our executive officers is determined by our board of directors based upon the recommendation of our compensation committee, aiming to attract and retain talent through competitive pay.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-15 | 72,516,011 | 12,722,258 | 61,328 | 85.07% | Passed |
| 2025 | 2025-06-23 | 67,071,290 | 6,289,601 | 98,174 | 91.43% | Passed |
| 2024 | 2024-06-20 | 63,842,175 | 5,876,101 | 8,451 | 91.57% | Passed |
| 2023 | 2023-06-13 | 51,710,250 | 13,676,178 | 64,553 | 79.08% | Passed |
| 2022 | 2022-06-23 | 91,740,768 | 12,563,596 | 280,169 | 87.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-15 | 85.07%a |
| 2025 | 2025-06-23 | 91.43%b |
| 2024 | 2024-06-20 | 91.57%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting outcome.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 17 : 1 |
|---|---|
| CEO total compensation | $6,811,754 |
| Median employee compensation | $411,028 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Arthur S. LeibowitzIndependent · Compensation · Nominating/Governance · Audit (Chair) | $138,606 | $175,000 | — | — | — | $313,606 |
| Jon GiacominIndependent · Compensation · Nominating/Governance (Chair) · Audit | 94,808 | 175,000 | — | — | — | 269,808 |
| Garrett LustigIndependent · Compensation · Nominating/Governance · Research & Development | 77,500 | 175,000 | — | — | — | 252,500 |
| Michele KorfinIndependent · Compensation · Research & Development | 75,192 | 175,000 | — | — | — | 250,192 |
| Prathyusha DuraibabuIndependent · Compensation · Research & Development · Audit | 74,808 | 175,000 | — | — | — | 249,808 |
| Gilberto QuinteroIndependent · Nominating/Governance · Research & Development (Chair) · Audit | 73,702 | 175,000 | — | — | — | 248,702 |
| Michael J. DriscollIndependent · Nominating/Governance · Audit | 67,692 | 175,000 | — | — | — | 242,692 |
| Alan A. AdesIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Robert AdesNot independent | 0 | 0 | 0 | — | 0 | 0 |
| Gary S. Gillheeney SrEmployee director | — | — | — | — | — | 0 |
| David EraniIndependent · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Glenn H. NussdorfNot independent | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $175,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 40,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $602,308 |
| Equity awards (grant-date value) | $1,225,000 |
| All other compensation | $0 |
| Total cost of the board | $1,827,308 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Organogenesis Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Organogenesis Holdings.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Pacira BioSciences, Inc. | 2025 | Frank Lee | $935,308 | $9,215,500 | $0 | $738,810 | $11,636,917 |
| 2 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 3 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 4 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 5 | Embecta Corp. | 2025 | Devdatt Kurdikar | 976,923 | 7,000,008 | 0 | 1,399,540 | 9,400,088 |
| 6 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 7 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | AxoGen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 9 | CONMED Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 10 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 11 | ZimVie Inc. | 2024 | Vafa Jamali | 818,461 | 6,367,343 | 0 | 0 | 7,209,869 |
| 12 | MiMedx Group, Inc. | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 13 | Artivion, Inc | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 14 | Organogenesis Holdings | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 15 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 16 | Bioventus Inc. | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 17 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 18 | Vanda Pharmaceuticals Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 19 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 20 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 21 | Anika Therapeutics, Inc. | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Organogenesis Holdings | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Anika Therapeutics, Inc. | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Artivion, Inc | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| AxoGen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Bioventus Inc. | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| CONMED Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Embecta Corp. | 110.2% | not disclosed | No | Korn Ferry |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| MiMedx Group, Inc. | 115% | not disclosed | No | Willis Towers Watson |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Vanda Pharmaceuticals Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| ZimVie Inc. | 0% | RSU 100 | not disclosed | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gary Gillheeney | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 6,811,754. Filing ↗machine: r2 · c31 · span 316005–316014 |
| 2 | Section 01, Brian Grow | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,143,490. Filing ↗machine: r14 · c31 · span 343634–343643 |
| 3 | Section 01, Patrick Bilbo | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,116,928. Filing ↗machine: r8 · c31 · span 330125–330134 |
| 4 | Section 01, Lori Freedman | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 2,042,879. Filing ↗machine: r11 · c31 · span 336886–336895 |
| 5 | Section 01, David Francisco | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Summary Compensation Table for Fiscal Year 2025”. As printed: 1,987,065. Filing ↗machine: r5 · c31 · span 323165–323174 |
| 6 | Section 03, Gary Gillheeney RSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 365286–365295 |
| 7 | Section 03, Brian Grow PSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 401139–401145 |
| 8 | Section 03, Patrick Bilbo RSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 382036–382043 |
| 9 | Section 03, Lori Freedman PSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 392770–392776 |
| 10 | Section 03, Lori Freedman RSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 390408–390415 |
| 11 | Section 03, Brian Grow RSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 398777–398784 |
| 12 | Section 03, David Francisco PSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 376026–376032 |
| 13 | Section 03, Gary Gillheeney PSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 367651–367658 |
| 14 | Section 03, David Francisco RSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 373664–373671 |
| 15 | Section 03, Patrick Bilbo PSU | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 384398–384404 |
| 16 | Section 03, Gary Gillheeney OPTION | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 362880–362889 |
| 17 | Section 03, Lori Freedman OPTION | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 388004–388011 |
| 18 | Section 03, Brian Grow OPTION | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 396373–396380 |
| 19 | Section 03, David Francisco OPTION | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 371260–371267 |
| 20 | Section 03, Patrick Bilbo OPTION | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 379632–379639 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “CEO Pay Ratio”. As printed: 17 : 1. Filing ↗ |
| 22 | Section 08, Arthur S. Leibowitz | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 313,606. Filing ↗machine: span 172141–172148 |
| 23 | Section 08, Jon Giacomin | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 269,808. Filing ↗machine: span 169968–169975 |
| 24 | Section 08, Garrett Lustig | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 252,500. Filing ↗machine: span 173237–173244 |
| 25 | Section 08, Michele Korfin | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 250,192. Filing ↗machine: span 171064–171071 |
| 26 | Section 08, Prathyusha Duraibabu | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 249,808. Filing ↗machine: span 166708–166715 |
| 27 | Section 08, Gilberto Quintero | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 248,702. Filing ↗machine: span 175432–175439 |
| 28 | Section 08, Michael J. Driscoll | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 242,692. Filing ↗machine: span 167781–167788 |
| 29 | Section 08, Alan A. Ades | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 08, Robert Ades | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 31 | Section 08, Gary S. Gillheeney Sr | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 08, David Erani | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 33 | Section 08, Glenn H. Nussdorf | DEF 14A | 2026-04-30 | 0001193125-26-197357 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 06, 2026 vote | Form 8-K | 2026-06-16 | 0001193125-26-272710 | Item 5.07 · say-on-pay result. As reported: 85.07% (votes for as printed: 72,516,011). Filing ↗ |
| 35 | Section 06, 2025 vote | Form 8-K | 2025-06-24 | 0001193125-25-145767 | Item 5.07 · say-on-pay result. As reported: 91.43% (votes for as printed: 67,071,290). Filing ↗ |
| 36 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0001193125-24-165670 | Item 5.07 · say-on-pay result. As reported: 91.57% (votes for as printed: 63,842,175). Filing ↗ |
| 37 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 38 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 39 | Section 09b board cost (computed) | Computed | — | — | Cash 602,308 + equity 1,225,000 + all other 0 = 1,827,308, summed across the director compensation table rows.machine: formula: Σ = 1,827,308 |
| 40 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 41 | Nevro Corp., Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044100 | CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993 |
| 42 | Alphatec Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 43 | Avanos Medical, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-027106 | CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. Filing ↗machine: r1 · c53 · span 1674377–1674386 |
| 44 | Embecta Corp., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046025 | CEO total compensation as printed in Embecta Corp.'s own proxy. As printed: 9,400,088. Filing ↗machine: r2 · c25 · span 968408–968417 |
| 45 | Integra LifeSciences Holdings Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0000917520-26-000015 | CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. Filing ↗machine: r2 · c30 · span 880204–880213 |
| 46 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 47 | AxoGen, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0000805928-26-000057 | CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318 |
| 48 | CONMED Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000816956-26-000047 | CEO total compensation as printed in CONMED Corporation's own proxy. As printed: 7,634,873. Filing ↗machine: r3 · c27 · span 1186564–1186573 |
| 49 | Orthofix Medical Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191716 | CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. Filing ↗machine: t96 · r4 · c16 · span 1472329–1472338 |
| 50 | ZimVie Inc., Section 10b CEO total | DEF 14A | 2025-03-25 | 0001193125-25-061931 | CEO total compensation as printed in ZimVie Inc.'s own proxy. As printed: 7,209,869. Filing ↗machine: r4 · c27 · span 677156–677165 |
| 51 | MiMedx Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001376339-26-000033 | CEO total compensation as printed in MiMedx Group, Inc.'s own proxy. As printed: 7,182,208. Filing ↗machine: t18 · r2 · c29 · span 444167–444176 |
| 52 | Artivion, Inc, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion, Inc's own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 53 | Organogenesis Holdings (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197357 | CEO total compensation as printed in Organogenesis Holdings's own proxy. As printed: 6,811,754. Filing ↗machine: r2 · c31 · span 316005–316014 |
| 54 | AngioDynamics, Inc., Section 10b CEO total | DEF 14A | 2026-10-08 | 0001140361-26-039022 | CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. Filing ↗machine: r2 · c27 · span 739870–739879 |
| 55 | Bioventus Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001665988-26-000014 | CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. Filing ↗machine: t53 · r2 · c28 · span 430404–430413 |
| 56 | OraSure Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 57 | Vanda Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026893 | CEO total compensation as printed in Vanda Pharmaceuticals Inc.'s own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705 |
| 58 | Tactile Systems Technology, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001104659-26-034206 | CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806 |
| 59 | Paragon 28, Inc., Section 10b CEO total | DEF 14A | 2024-04-05 | 0001193125-24-088613 | CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. Filing ↗machine: t193 · r2 · c31 · span 598805–598814 |
| 60 | Anika Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017488 | CEO total compensation as printed in Anika Therapeutics, Inc.'s own proxy. As printed: 2,033,370. Filing ↗machine: r5 · c22 · span 1052517–1052526 |
| 61 | Section 10a, Integra LifeSciences Holdings Corporation reciprocity | DEF 14A | — | 0000917520-26-000015 | Integra LifeSciences Holdings Corporation's most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 62 | Section 10a, AxoGen, Inc. reciprocity | DEF 14A | — | 0000805928-26-000057 | AxoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 63 | Section 10a, MiMedx Group, Inc. reciprocity | DEF 14A | — | 0001376339-26-000033 | MiMedx Group, Inc. names Organogenesis Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 64 | Section 10a, Orthofix Medical Inc. reciprocity | DEF 14A | — | 0001193125-26-191716 | Orthofix Medical Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 65 | Section 10a, AngioDynamics, Inc. reciprocity | DEF 14A | — | 0001140361-26-039022 | AngioDynamics, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 66 | Section 10a, Paragon 28, Inc. reciprocity | DEF 14A | — | 0001193125-24-088613 | Paragon 28, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 67 | Section 10a, Nevro Corp. reciprocity | DEF 14A | — | 0000950170-24-044100 | Nevro Corp.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 68 | Section 10a, ZimVie Inc. reciprocity | DEF 14A | — | 0001193125-25-061931 | ZimVie Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 69 | Section 10a, Avanos Medical, Inc. reciprocity | DEF 14A | — | 0001104659-26-027106 | Avanos Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 70 | Section 10a, CONMED Corporation reciprocity | DEF 14A | — | 0000816956-26-000047 | CONMED Corporation's most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 71 | Section 10a, Vanda Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001628280-26-026893 | Vanda Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 72 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 73 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc. names Organogenesis Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 74 | Section 10a, Embecta Corp. reciprocity | DEF 14A | — | 0001140361-25-046025 | Embecta Corp.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 75 | Section 10a, Tactile Systems Technology, Inc. reciprocity | DEF 14A | — | 0001104659-26-034206 | Tactile Systems Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 76 | Section 10a, Alphatec Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-191867 | Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 77 | Section 10a, Anika Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-26-017488 | Anika Therapeutics, Inc. names Organogenesis Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 78 | Section 10a, Artivion, Inc reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion, Inc's most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |
| 79 | Section 10a, OraSure Technologies, Inc. reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Organogenesis Holdings. Filing ↗ |